Carbon‐13 labeling of ibrutinib for human microdosing
Authors:
- 30 November 2022
- journal article
- research article
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 66 (1) , 4-10
Abstract
Ibrutinib is an oral medication for the treatment of B cell malignancies. During its clinical development, a stable isotopologue of ibrutinib was required for the assessment of the drug's absolute oral bioavailability via intravenous microdosing. The following work describes a 10‐step, gram‐scale production of carbon‐13 labeled ibrutinib from [13C6]phenol (13C6, 99%) in 31% overall yield with >99% chemical purity and >99% enantiomeric excess (ee), suitable for intravenous microdosing in humans.Keywords
This publication has 14 references indexed in Scilit:
- Current and Emerging Treatments for Waldenström MacroglobulinemiaActa Haematologica, 2020
- Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19ACS Infectious Diseases, 2020
- Applications of Deuterium in Medicinal ChemistryJournal of Medicinal Chemistry, 2019
- Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluidJournal of Chromatography B, 2018
- Patent Review of Manufacturing Routes to Recently Approved Oncology Drugs: Ibrutinib, Cobimetinib, and AlectinibOrganic Process Research & Development, 2016
- Stable isotope‐labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adultsBritish Journal of Clinical Pharmacology, 2016
- Bioanalysis of Ibrutinib and its Active Metabolite in Human Plasma: Selectivity Issue, Impact Assessment and ResolutionBioanalysis, 2015
- Practical and Efficient Strategy for Evaluating Oral Absolute Bioavailability with an Intravenous Microdose of a Stable Isotopically-Labeled Drug Using a Selected Reaction Monitoring Mass Spectrometry AssayAnalytical Chemistry, 2012
- Calculation and Mitigation of Isotopic Interferences in Liquid Chromatography–Mass Spectrometry/Mass Spectrometry Assays and Its Application in Supporting Microdose Absolute Bioavailability StudiesAnalytical Chemistry, 2012
- Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine KinaseChemMedChem, 2006